Kyverna Therapeutics (KYTX) Current Leases (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Current Leases data on file, last reported at $1.8 million in Q1 2026.

• Quarterly Current Leases rose 247.93% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (up 247.93% YoY) and the FY2025 annual result came in at $3.7 million, up 15.85% from the prior year.
• Current Leases slipped to $1.8 million in Q1 2026, from $3.7 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $3.7 million in Q4 2025 to a low of $190000.0 in Q3 2025.
• A 4-year average of $1.4 million and a median of $991000.0 in 2024 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2025 — Current Leases plunged 79.59% — and 2026, when it jumped 247.93%.
• Tracing KYTX's Current Leases over 4 years: stood at $2.0 million in 2023, then surged by 60.95% to $3.2 million in 2024, then rose by 15.85% to $3.7 million in 2025, then plunged by 51.83% to $1.8 million in 2026.
• The last three Current Leases figures came in at $1.8 million (Q1 2026), $3.7 million (Q4 2025), and $190000.0 (Q3 2025), per Business Quant data.